Abstract 189P
Background
Inflammation-based score such as Glasgow prognostic score (GPS) or Neutrophil -Lymphocyte ratio (NLR) is associated with clinical outcome of cancer patients. However, the prognostic value of GPS and NLR for patients with advanced pancreatic cancer who received systemic chemotherapy remains unclear.
Methods
We conducted single center retrospective study. Inclusion criteria was defined as patients with metastatic or recurrent pancreatic cancer treated with FFX or GnP as first line treatment at Hokkaido university hospital between January 2014 and December 2018. Baseline GPS was identified that GPS 0 was CRP ≤1.0 mg/dL and Alb ≥3.5 g/dL, GPS 1 was CRP >1.0 mg/dL or Alb <3.5 g/dL, and GPS 2 was CRP >1.0 mg/dL and Alb <3.5 g/dL. NLR was defined as the ratio of absolute neutrophil count and absolute lymphocyte count. As no clear NLR cutoff level has been established in this setting, we used the cutoff ≧3. Cox-proportional hazards model were used to identify prognostic factors in univariate and multivariate analyses.
Results
A total of 101 patients were eligible. Median age of patients was 67, male/female was 63/38, ECOG PS 0/1/2 was 36/62/3, FFX/GnP was 19/82, GPS 0/1/2/unknown was 52/21/23/5, NLR ≧3/<3/unknown was 51/44/6, respectively. In GPS 0/1-2 patients, median PFS were 5.2/2.3months (HR 1.772, 95%CI 1.165-2.693, p=0.007), median OS were 12.4/5.7 months (HR 2.384, 95%CI 1.534-3.706, p<0.001), respectively. In NLR 3≧3 patients, median PFS were 6.4/2.6 months (HR 2.436, 95%C.I. 1.568-3.784, p<0.001), median OS were 14.6/6.0 months (HR 2.496, 95% C.I. 1.616-3.856, p<0.001), respectively. In multivariate analysis, High NLR (NLR ≧3 vs <3 : HR 2.067, 95%C.I. 1.278-3.343, p=0.003) was significantly associated with poor PFS. For OS, female (HR 2.006, 95%C.I. 1.206-3.34, p=0.007), liver metastasis (HR 2.137, 95%C.I. 1.281-3.565, p=0.004), high NLR (NLR ≧3 vs <3: HR 2.745, 95%C.I. 1.639-4.599, p<0.001), high GPS (GPS 0 vs 1-2: HR 2.016, 95%C.I. 1.233-3.296, p<0.001) were significantly associated with poor OS.
Conclusions
NLR may be better prognosticator than GPS for patients with metastatic or recurrent pancreatic cancer treated with FFX or GnP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Nakatsumi: Honoraria (self): Takeda; Honoraria (self): Sanofi; Honoraria (self): Merck Biopharma; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical. Y. Kawamoto: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Takeda; Honoraria (self): Chudai Pharma; Honoraria (self): Daiichi Sankyo; Honoraria (self): Merck; Honoraria (self): Lilly; Honoraria (self): Japan Agency for Medical Research and Development. S. Yuki: Honoraria (self): Takeda Pharmaceutical Co., Ltd.; Honoraria (self): Ono Pharmaceutical Co., Ltd.; Honoraria (self): Sanofi K.K.; Honoraria (self): Bayer Yakuin., Ltd.; Honoraria (self): Eli Lilly K.K.; Honoraria (self): Bristol-Myers Squibb Co., Ltd.; Honoraria (self): Merck Biopharma Co., Ltd.; Honoraria (self): Chudai Pharmaceutical Co., Ltd.; Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Yakult Honsha Co., Ltd.; Honoraria (self): MSD K.K. N. Sakamoto: Honoraria (self): Gilead Sciences; Honoraria (self): Chudai Pharm; Honoraria (self): Bayer AG; Honoraria (self): Otsuka Pharm; Honoraria (self): Daiichi-Sankyo; Honoraria (self): Astellas Pharma; Honoraria (self): Takeda; Honoraria (self): Eisai; Research grant/Funding (self): Gilead Sciences; Research grant/Funding (self): Eisai; Research grant/Funding (self): MSD; Research grant/Funding (self): Otsuka Pharm; Research grant/Funding (self): AbbVie; Research grant/Funding (self): Asuka Pharm. Y. Komatsu: Research grant/Funding (institution): Eisai; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Daiichi-Sankyo; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Yakult; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Chugai; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Taiho; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Lilly; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): MSD; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ono; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Nipro; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Asahikasei; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Nihonkayaku; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Takeda; Honoraria (self), Research grant/Funding (self): Bayer; Honoraria (self): Kyowa Kirin; Honoraria (self): Merck Biopharma; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Shire Japan; Honoraria (self): Novartis Pharma; Honoraria (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session